Fifth Third Bancorp (FITB) Stock Price Declined While Basswood Capital Management Has Lowered Position; Galectin Therapeutics (GALT) Stock Declined While Sabby Management Cut Its Holding by $776,226

September 14, 2018 - By Margaret Staats

Fifth Third Bancorp (NASDAQ:FITB) Logo

Sabby Management Llc decreased its stake in Galectin Therapeutics Inc (GALT) by 90.22% based on its latest 2018Q2 regulatory filing with the SEC. Sabby Management Llc sold 129,371 shares as the company’s stock declined 31.07% while stock markets rallied. The hedge fund held 14,029 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $89,000, down from 143,400 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Galectin Therapeutics Inc for a number of months, seems to be less bullish one the $222.98 million market cap company. The stock increased 1.68% or $0.09 during the last trading session, reaching $5.45. About 351,181 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 208.00% since September 14, 2017 and is uptrending. It has outperformed by 192.38% the S&P500. Some Historical GALT News: 11/05/2018 – GALECTIN THERAPEUTICS – HAS ENOUGH CASH TO FUND CURRENTLY PLANNED OPERATIONS, RESEARCH & DEVELOPMENT ACTIVITIES THROUGH AT LEAST MARCH 31, 2019; 19/04/2018 – DJ Galectin Therapeutics Inc, Inst Holders, 1Q 2018 (GALT); 29/03/2018 – GALECTIN THERAPEUTICS – BELIEVES HAS SUFFICIENT CASH TO FUND CURRENTLY PLANNED OPS & RESEARCH & DEVELOPMENT ACTIVITIES THROUGH AT LEAST MARCH 31, 2019; 14/05/2018 – GALECTIN THERAPEUTICS INC – “DISAGREE WITH FDA’S DECISION NOT TO GRANT BREAKTHROUGH THERAPY DESIGNATION AT THIS TIME”; 14/05/2018 – GALECTIN THERAPEUTICS TO STUDY GR-MD-02 FOR NASH CIRRHOSIS; 14/05/2018 – GALECTIN THERAPEUTICS MOVES GR-MD-02 TO PHASE 3 DEVELOPMENT; 12/04/2018 – Galectin Therapeutics Closes Below 50-Day Average: Technicals; 16/04/2018 – GALT: GR-MD-02 SHOWED STAT SIG IMPROVEMENT IN PORTAL PRESSURE; 11/05/2018 – Galectin Therapeutics 1Q Loss $4.3M; 16/04/2018 – Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects

Basswood Capital Management Llc decreased its stake in Fifth Third Bancorp (FITB) by 30.61% based on its latest 2018Q2 regulatory filing with the SEC. Basswood Capital Management Llc sold 61,348 shares as the company’s stock declined 7.32% while stock markets rallied. The hedge fund held 139,052 shares of the major banks company at the end of 2018Q2, valued at $3.99 million, down from 200,400 at the end of the previous reported quarter. Basswood Capital Management Llc who had been investing in Fifth Third Bancorp for a number of months, seems to be less bullish one the $19.36 billion market cap company. The stock increased 0.97% or $0.28 during the last trading session, reaching $29.05. About 2.51 million shares traded. Fifth Third Bancorp (NASDAQ:FITB) has risen 10.28% since September 14, 2017 and is uptrending. It has underperformed by 5.34% the S&P500. Some Historical FITB News: 24/04/2018 – FIFTH THIRD BANCORP – RESULTS INCLUDED A NET POSITIVE $0.40 IMPACT ON REPORTED 1Q18 EPS; 22/03/2018 – Fifth Third Closes Below 50-Day Moving Average: Technicals; 21/05/2018 – FIFTH THIRD BANCORP – EXPECT INVESTMENT TO GENERATE AN IRR OF APPROXIMATELY 18.5 PERCENT; 02/04/2018 – GreenSky is Also Considering Another Private Share Sale Instead of a Listing; 21/05/2018 – FIFTH THIRD BANCORP TO MERGE WITH MB FINANCIAL, INC. CREATING A LEADING RETAIL AND COMMERCIAL FRANCHISE IN THE ATTRACTIVE CHICAGO MARKET; 24/05/2018 – FIFTH THIRD BANCORP – EXPECTS SETTLEMENT OF TRANSACTION TO OCCUR ON OR BEFORE JUNE 18; 21/05/2018 – Fifth Third Bancorp Expects Merger to Reduce Co’s Regulatory Common Equity Tier 1 Ratio by About 45 Basis Points; 21/05/2018 – FIFTH THIRD BANCORP – SEES COST SAVINGS FROM CONSOLIDATION OF SOME BACK OFFICE LOCATIONS, ABOUT 20% COMBINED CHICAGO BRANCHES FROM MB FINANCIAL DEAL; 19/04/2018 – DJ Fifth Third Bancorp, Inst Holders, 1Q 2018 (FITB); 02/04/2018 – Financial-Technology Firm May Seek to Raise $1 Billion at Valuation of $5 Billion

Investors sentiment decreased to 1.5 in 2018 Q2. Its down 0.36, from 1.86 in 2018Q1. It is negative, as 7 investors sold GALT shares while 11 reduced holdings. 13 funds opened positions while 14 raised stakes. 4.60 million shares or 14.35% more from 4.02 million shares in 2018Q1 were reported. Tower Rech Cap (Trc) holds 1,094 shares. Art Advsrs Ltd Liability has invested 0.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Royal Bancshares Of Canada invested in 1,600 shares. Manufacturers Life Insurance Commerce The reported 0% stake. Salem Invest Counselors stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Pnc Services Group holds 52,164 shares. Morgan Stanley reported 61,337 shares. Cwm Limited Liability Corp stated it has 2,000 shares or 0% of all its holdings. Susquehanna Intl Ltd Liability Partnership holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 357,793 shares. Barclays Public Limited Company owns 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 3,194 shares. Lpl Fincl Limited owns 30,793 shares. The Missouri-based Cutter Co Brokerage has invested 0.13% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Da Davidson stated it has 0.08% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Stratos Wealth Prtn Ltd reported 0.01% stake. National Bank & Trust Of Montreal Can accumulated 75,500 shares.

Since April 4, 2018, it had 1 buying transaction, and 25 insider sales for $14.97 million activity. 151,860 shares were sold by CZIRR JAMES C, worth $1.31M. $751,000 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was sold by TRABER PETER G. CALLICUTT JACK W had sold 3,349 shares worth $16,745 on Wednesday, April 4. The insider 10X Fund – L.P. sold 50,000 shares worth $256,081. On Friday, June 8 Shlevin Harold H. sold $671,988 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) or 115,054 shares. Another trade for 19,370 shares valued at $116,585 was sold by OMENN GILBERT S.

Analysts await Galectin Therapeutics, Inc. (NASDAQ:GALT) to report earnings on November, 6. They expect $-0.10 EPS, up 23.08% or $0.03 from last year’s $-0.13 per share. After $-0.11 actual EPS reported by Galectin Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

Sabby Management Llc, which manages about $835.79M and $647.22M US Long portfolio, upped its stake in Unum Therapeutics Inc by 318,708 shares to 581,303 shares, valued at $8.34 million in 2018Q2, according to the filing. It also increased its holding in Esperion Therapeutics Inc (Put) by 935 shares in the quarter, for a total of 6,988 shares, and has risen its stake in Global Blood Therapeutics Inc (Call).

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. The stock has “Neutral” rating by H.C. Wainwright on Thursday, September 29. H.C. Wainwright initiated Galectin Therapeutics, Inc. (NASDAQ:GALT) on Monday, September 21 with “Buy” rating. The firm has “Buy” rating by Roth Capital given on Thursday, December 7. The firm earned “Sell” rating on Wednesday, September 28 by TH Capital. The rating was downgraded by Roth Capital on Wednesday, September 28 to “Sell”. The stock has “Buy” rating by H.C. Wainwright on Wednesday, June 14. The firm earned “Buy” rating on Thursday, March 30 by H.C. Wainwright. The firm has “Mkt Perform” rating given on Monday, October 3 by FBR Capital. The rating was reinitiated by H.C. Wainwright on Monday, March 28 with “Buy”. On Thursday, January 4 the stock rating was maintained by Roth Capital with “Buy”.

More recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Seekingalpha.com which released: “NASH Cirrhosis: The Real NASH Epidemic” on August 28, 2018. Also Benzinga.com published the news titled: “52 Biggest Movers From Friday” on September 10, 2018. Nasdaq.com‘s news article titled: “Galectin Therapeutics to Present at HC Wainwright 20th Annual Global Investment Conference” with publication date: August 28, 2018 was also an interesting one.

More important recent Fifth Third Bancorp (NASDAQ:FITB) news were published by: Nasdaq.com which released: “7 Big Bank Stocks That Are Breaking Down” on September 12, 2018, also Benzinga.com published article titled: “MB Financial Acquisition Makes Fifth Third A Buy, Wedbush Says In Upgrade”, Bizjournals.com published: “Fifth Third: Why we bought Chapel Hill’s Franklin Street Partners” on August 31, 2018. More interesting news about Fifth Third Bancorp (NASDAQ:FITB) was released by: Bizjournals.com and their article: “Fifth Third to buy Chapel Hill’s Franklin Street Partners” with publication date: August 29, 2018.

Analysts await Fifth Third Bancorp (NASDAQ:FITB) to report earnings on October, 23 before the open. They expect $0.64 EPS, up 33.33% or $0.16 from last year’s $0.48 per share. FITB’s profit will be $426.45M for 11.35 P/E if the $0.64 EPS becomes a reality. After $0.63 actual EPS reported by Fifth Third Bancorp for the previous quarter, Wall Street now forecasts 1.59% EPS growth.

Among 34 analysts covering Fifth Third (NASDAQ:FITB), 8 have Buy rating, 1 Sell and 25 Hold. Therefore 24% are positive. Fifth Third had 118 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Bank of America on Wednesday, October 25. The stock of Fifth Third Bancorp (NASDAQ:FITB) earned “Hold” rating by Robert W. Baird on Tuesday, May 22. RBC Capital Markets maintained the stock with “Buy” rating in Thursday, June 22 report. The rating was maintained by BMO Capital Markets on Friday, December 8 with “Hold”. The stock of Fifth Third Bancorp (NASDAQ:FITB) earned “Neutral” rating by Nomura on Wednesday, April 25. The rating was downgraded by Evercore on Friday, April 1 to “Hold”. Oppenheimer maintained the stock with “Outperform” rating in Tuesday, October 6 report. The stock of Fifth Third Bancorp (NASDAQ:FITB) has “Buy” rating given on Thursday, September 7 by RBC Capital Markets. The firm earned “Sell” rating on Friday, October 6 by UBS. The rating was maintained by RBC Capital Markets on Thursday, July 27 with “Buy”.

Since March 16, 2018, it had 0 insider purchases, and 1 insider sale for $134,400 activity. Immaneni Aravind sold 4,000 shares worth $134,400.

Basswood Capital Management Llc, which manages about $2.47B and $2.12B US Long portfolio, upped its stake in Onemain Hldgs Inc by 152,024 shares to 3.04 million shares, valued at $101.22 million in 2018Q2, according to the filing. It also increased its holding in Codorus Vy Bancorp Inc (NASDAQ:CVLY) by 149,002 shares in the quarter, for a total of 349,593 shares, and has risen its stake in Ally Finl Inc (NYSE:ALLY).

Investors sentiment increased to 1.2 in Q2 2018. Its up 0.48, from 0.72 in 2018Q1. It increased, as 31 investors sold FITB shares while 189 reduced holdings. 71 funds opened positions while 192 raised stakes. 544.00 million shares or 0.58% less from 547.18 million shares in 2018Q1 were reported. Tiaa Cref Invest Mgmt Ltd Co has 0.04% invested in Fifth Third Bancorp (NASDAQ:FITB) for 2.15M shares. Hl Financial Serv Lc has invested 0.03% of its portfolio in Fifth Third Bancorp (NASDAQ:FITB). Royal Retail Bank Of Canada reported 0.03% in Fifth Third Bancorp (NASDAQ:FITB). Fmr Ltd Liability Company holds 0% or 1.09M shares. Ls Invest Advsr Ltd Liability Corporation invested in 33,115 shares. Comerica Bankshares holds 331,848 shares. Ny State Teachers Retirement Systems accumulated 1.21M shares. Livforsakringsbolaget Skandia Omsesidigt holds 35,613 shares or 0.09% of its portfolio. Wealthtrust Axiom Ltd holds 1.48% or 146,187 shares. Baldwin Brothers Incorporated Ma holds 2,164 shares. Caisse De Depot Et Placement Du Quebec holds 0.01% or 115,690 shares. Cibc Asset Management has 70,844 shares for 0.01% of their portfolio. Farmers Bancshares holds 0.07% or 4,044 shares in its portfolio. Northern Tru Corp, a Illinois-based fund reported 9.12M shares. Douglass Winthrop Advisors Lc has 62,313 shares.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts